SCHAFFHAUSEN, Switzerland, Sept. 29, 2015 /CNW/ - Occlutech, a leading innovator of implants to treat structural heart disease today announced that it has obtained European CE Mark approval for its dedicated muscular Ventricle Septal Defect Closure Device, (VSD). The device is a specifically designed implant indicated for the minimally invasive closure of muscular Ventricle Septal Defects, VSD.
Tor Peters, CEO of Occlutech Group, commented: "We are extremely pleased to be able to provide patients and cardiologists with this innovative product and expect our VSD occluder to significantly add and improve therapy options for this patient population."
Occlutech's muscular VSD occluder consists of a flexible nitinol wire mesh with "shape-memory" properties. Occlutech´s proprietary technology allows for the creation of products with unique properties regarding flexibility and adaptability. The implant will be available in different configurations, multiple sizes, and can accommodate a broad range of defects. The Occlutech mVSD implant allows fast, atraumatic, minimally invasive closure of these defects. VSD closure using implantable devices is an alternative to open heart surgery.
Occlutech is a global leader in developing innovative products for the treatment of structural heart disease. The Company sells and markets ASD, PFO, PLD and PDA occluders, as well as a range of specialized occlusion devices and accessories in over 80 countries around the world. Occlutech has several innovative products under development and operates facilities in Germany, Turkey and Sweden. For additional information please visit Occlutech´s website at http://www.occlutech.com.
SOURCE Occlutech International AB